Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.09 USD | 0.00% | +28.75% | +74.58% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+74.58% | 578M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating